San Francisco, CA, October 22, 2018 – Enable Biosciences Inc. has moved to a new location in South San Francisco to accommodate growth and to launch a new clinical testing facility.
Since 2016, Enable Biosciences has been housed at MBC Biolabs, a biotechnology incubator located in the Dogpatch neighborhood in San Francisco. Now a team of six scientists, engineers, and physicians, Enable plans to expand to include clinical scientists in anticipation of the launch of their blood and saliva tests for type 1 diabetes, lyme disease, and food allergy over the next year. The new facility spans 3,488 square feet over two floors, with refurbished lab facilities and office space.
“MBC Biolabs will always have a special place in our hearts as the absolute best place in the world to start a biotech company,” said David Seftel, Enable’s CEO, “We were very fortunate to have begun our journey there and we will maintain strong relationships with the brilliant scientists and entrepreneurs we met while in residence.”
“Our new facility is essential to our future growth as we transition from a pure research company to one providing high-quality clinical testing,” said Peter Robinson, Enable’s Chief Scientific Officer, “Thanks to our investment in automation, we will be able to support a significant amount of testing capacity at this location while maintaining our existing research programs.”
About Enable Biosciences: Enable Biosciences is a San Francisco-based diagnostics company commercializing licensed technology from UC Berkeley and Stanford University. Enable develops ultrasensitive and multiplex immunoassays to help diagnose diseases at their earliest and most effectively treatable stages. For more about Enable, visit www.enablebiosciences.com. For press inquiries, email email@example.com or call Peter Robinson, PhD (415-967-1460).